180 related articles for article (PubMed ID: 15540238)
1. Acceptance of tamoxifen chemoprevention by physicians and women at risk.
McKay A; Latosinsky S; Martin W
Cancer; 2005 Jan; 103(1):209-10. PubMed ID: 15540238
[No Abstract] [Full Text] [Related]
2. Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors.
Bober SL; Hoke LA; Duda RB; Regan MM; Tung NM
J Clin Oncol; 2004 Dec; 22(24):4951-7. PubMed ID: 15598980
[TBL] [Abstract][Full Text] [Related]
3. Acceptance of tamoxifen chemoprevention by physicians and women at risk.
Tchou J; Hou N; Rademaker A; Jordan VC; Morrow M
Cancer; 2004 May; 100(9):1800-6. PubMed ID: 15112259
[TBL] [Abstract][Full Text] [Related]
4. The current status of breast cancer chemoprevention: a star is born.
Morrow M; Jordan VC
J Surg Oncol; 2007 Jan; 95(1):4-5. PubMed ID: 17192883
[No Abstract] [Full Text] [Related]
5. Chemoprevention Indication Score: a user-friendly tool for prevention of breast cancer - pilot analysis.
Layeequr Rahman R; Crawford S
Breast; 2009 Oct; 18(5):289-93. PubMed ID: 19716702
[TBL] [Abstract][Full Text] [Related]
6. Chemoprevention of breast cancer: recommendations and rationale.
Am Fam Physician; 2003 Mar; 67(6):1309-14. PubMed ID: 12674459
[No Abstract] [Full Text] [Related]
7. Women's decision making about whether or not to use breast cancer chemoprevention.
Altschuler A; Somkin CP
Women Health; 2005; 41(2):81-95. PubMed ID: 16219589
[TBL] [Abstract][Full Text] [Related]
8. Chemoprevention of breast cancer for women at high risk.
Chan K; Morris GJ
Semin Oncol; 2006 Dec; 33(6):642-6. PubMed ID: 17145342
[TBL] [Abstract][Full Text] [Related]
9. Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction.
Melnikow J; Paterniti D; Azari R; Kuenneth C; Birch S; Kuppermann M; Nuovo J; Keyzer J; Henderson S
Cancer; 2005 May; 103(10):1996-2005. PubMed ID: 15825209
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen or raloxifene for breast cancer chemoprevention: a tale of two choices--point.
Jordan VC
Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2207-9. PubMed ID: 18006908
[No Abstract] [Full Text] [Related]
11. Keeping breast cancer at bay. Women at risk are asked to weigh the pros and cons of a prevention pill.
Brink S
US News World Rep; 1999 May; 126(21):76. PubMed ID: 10387894
[No Abstract] [Full Text] [Related]
12. Psychological and clinical factors implicated in decision making about a trial of low-dose tamoxifen in hormone replacement therapy users.
Rondanina G; Puntoni M; Severi G; Varricchio C; Zunino A; Feroce I; Bonanni B; Decensi A
J Clin Oncol; 2008 Mar; 26(9):1537-43. PubMed ID: 18349406
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen for breast cancer risk reduction: impact of alternative approaches to quality-of-life adjustment on cost-effectiveness analysis.
Melnikow J; Birch S; Slee C; McCarthy TJ; Helms LJ; Kuppermann M
Med Care; 2008 Sep; 46(9):946-53. PubMed ID: 18725849
[TBL] [Abstract][Full Text] [Related]
14. Tamoxifen chemoprevention and cardiac disease.
Narod SA; Iqbal J
J Clin Oncol; 2011 Aug; 29(22):3106-7; author reply 3107. PubMed ID: 21709203
[No Abstract] [Full Text] [Related]
15. Tamoxifen: an enduring star.
Veronesi U; Maisonneuve P; Decensi A
J Natl Cancer Inst; 2007 Feb; 99(4):258-60. PubMed ID: 17312297
[No Abstract] [Full Text] [Related]
16. Tamoxifen (TAM): the dispute goes on.
Grilli S
Ann Ist Super Sanita; 2006; 42(2):170-3. PubMed ID: 17033137
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen and breast cancer prevention: what should you tell your patients?
Goel V
CMAJ; 1998 Jun; 158(12):1615-7. PubMed ID: 9645176
[No Abstract] [Full Text] [Related]
18. Breast cancer risk assessment and risk reduction.
Newman LA; Vogel VG
Surg Clin North Am; 2007 Apr; 87(2):307-16, vii-viii. PubMed ID: 17498528
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N
J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118
[TBL] [Abstract][Full Text] [Related]
20. Myxoid leiomyosarcoma of the uterus in a patient receiving tamoxifen therapy: a case report.
Botsis D; Koliopoulos C; Kondi-Pafitis A; Creatsas G
Int J Gynecol Pathol; 2006 Apr; 25(2):173-5. PubMed ID: 16633068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
